Sign in to view Belén’s full profile Belén can introduce you to 10+ people at Sanofi New to LinkedIn? Join now By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . Sign in to view Belén’s full profile Belén can introduce you to 10+ people at Sanofi New to LinkedIn? Join now By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . Chief Executive Officer of Sanofi Greater Paris Metropolitan Region Contact Info Sign in to view Belén’s full profile Belén can introduce you to 10+ people at Sanofi Sign in with Email or New to LinkedIn? Join now By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . 176K followers 500+ connections Sign in to view Belén’s full profile Belén can introduce you to 10+ people at Sanofi New to LinkedIn? Join now By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . See your mutual connections View mutual connections with Belén Belén can introduce you to 10+ people at Sanofi Sign in with Email or New to LinkedIn? Join now By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . View mutual connections with Belén Belén can introduce you to 10+ people at Sanofi New to LinkedIn? Join now By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . Sign in to view Belén’s full profile Belén can introduce you to 10+ people at Sanofi New to LinkedIn? Join now By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . Report this profile As CEO of Sanofi, I have the honor of leading our next phase of growth, grounded in a deep commitment to the patients we serve. I'm proud to lead a team of dedicated colleagues worldwide who bring this mission to life each day for the patients counting on us. External positions - L’Oréal SA, (publicly listed company), Independent Director of the Board - Banco Bilbao Vizcaya Argentaria S.A., (publicly listed company), Independent Director of the Board - German Chemical Industry Association (VCI), Member of the Executive Committee - European Round Table for Industry, Member - The Business Council, Active Member Articles by Belén The world needs ‘precision globalization’. Pharma is showing the way. Dec 12, 2025 The world needs ‘precision globalization’. Pharma is showing the way. Adoption of a multimodality strategy has enabled pharma to do something once considered impossible: treat the patient… 386 6 Comments The world needs ‘precision globalization’. Pharma is showing the way. Adoption of a multimodality strategy has enabled pharma to do something once considered impossible: treat the patient… Stop National Solo Efforts in Europe! Jul 14, 2025 Stop National Solo Efforts in Europe! Europe is under pressure. Geopolitical tensions are rising. 1,129 63 Comments Stop National Solo Efforts in Europe! Europe is under pressure. Geopolitical tensions are rising. Why trust-based leadership is key to thriving in the Intelligent Age Jan 21, 2025 Why trust-based leadership is key to thriving in the Intelligent Age The Intelligent Age will change how people live and work, as well as how products are developed and made, making… 732 18 Comments Why trust-based leadership is key to thriving in the Intelligent Age The Intelligent Age will change how people live and work, as well as how products are developed and made, making… Leadership in the Bioconvergence Revolution Nov 8, 2024 Leadership in the Bioconvergence Revolution Throughout the modern history of science, disciplines such as biology and chemistry operated mainly in isolation… 337 19 Comments Leadership in the Bioconvergence Revolution Throughout the modern history of science, disciplines such as biology and chemistry operated mainly in isolation… How to thrive in this new era of trust-driven leadership Apr 11, 2024 How to thrive in this new era of trust-driven leadership Our global society faces many significant risks in 2024, including the devastating wars in the Middle East and Europe… 610 7 Comments How to thrive in this new era of trust-driven leadership Our global society faces many significant risks in 2024, including the devastating wars in the Middle East and Europe… Generative AI and Data Culture Oct 23, 2023 Generative AI and Data Culture For 355 years, Merck Group has pushed the boundaries of human progress with the best available technologies. In the… 958 35 Comments Generative AI and Data Culture For 355 years, Merck Group has pushed the boundaries of human progress with the best available technologies. In the… Mutualism: The right path to de-risk our collective future Jul 20, 2023 Mutualism: The right path to de-risk our collective future In recent months, I’ve spent significant time talking with business and government leaders worldwide about the current… 494 11 Comments Mutualism: The right path to de-risk our collective future In recent months, I’ve spent significant time talking with business and government leaders worldwide about the current… Three things will enable society to thrive in the 21st century Apr 13, 2023 Three things will enable society to thrive in the 21st century A cascading series of global crises and conflicts starting with the Covid-19 pandemic has made our world much more… 1,229 20 Comments Three things will enable society to thrive in the 21st century A cascading series of global crises and conflicts starting with the Covid-19 pandemic has made our world much more… Does the future of science lie in bioconvergence? Jan 5, 2023 Does the future of science lie in bioconvergence? Public confidence in science and trust in scientists has rarely been higher than it is today. Worldwide, most people… 530 13 Comments Does the future of science lie in bioconvergence? Public confidence in science and trust in scientists has rarely been higher than it is today. Worldwide, most people… The Three Dimensions of Resilience Sep 2, 2022 The Three Dimensions of Resilience Have you noticed that some companies thrive while others only endure during times of change, complexity, and… 1,580 35 Comments The Three Dimensions of Resilience Have you noticed that some companies thrive while others only endure during times of change, complexity, and… Belén Garijo Belén Garijo 2w Report this post Belén Garijo shared this September has a way of sharpening focus. And this September, we are ready. With a new Executive Committee in place, built for faster decision-making and clearer accountability, we are at work on what comes next for Sanofi . This team carries two responsibilities simultaneously: delivering strong performance today and building the foundations for our next decade. Both matter. Neither can wait. What drives me, and all of us, is the commitment of our people, our unwavering belief in the power of science, and the patients counting on us. That is what this company is built on. The work continues, and I am proud to do it with this team! public_profile__posts 3,453 59 Comments Copy LinkedIn Facebook X Report this post Belén Garijo reposted this Report this post Belén Garijo reposted this Sanofi Sanofi 4w Belén Garijo reposted this Today, we’re proud to welcome Sanofi’s new Executive Committee, led by Belén Garijo . A team bringing together diverse expertise and experiences, united by a shared vision for what comes next. 🟣 Manuela Buxo , EVP, Head of Specialty Care 🟣 Paulo Fontoura , EVP, Head of Research and Development 🟣 Thomas Grenier , EVP, General Medicines 🟣 Jamie Haney , EVP, General Counsel 🟣 Veronique JAILLET, Interim Chief People Officer 🟣 Brendan O'Callaghan , EVP, Manufacturing and Supply 🟣 François-Xavier Roger , EVP, Chief Financial Officer 🟣 Thomas Triomphe , EVP, Vaccines This marks the beginning of a new chapter. And there’s plenty more to discover along the way. Welcome to our new Executive Committee! Learn more about the team: http://spkl.io/60477uHuU public_profile__posts 2,313 54 Comments Copy LinkedIn Facebook X Report this post Belén Garijo Belén Garijo 2mo Report this post Belén Garijo shared this Today, we published our strong half-year results. Today also marks 12 weeks back at Sanofi — and what a journey it has been! Our foundations are solid: strong science, talented people, and a global footprint that sets us apart. Now, the work ahead is clear, focusing our strengths on where we can have the greatest potential impact for patients. The disciplined choices we make now, in the face of real challenges and rising expectations, will define our next chapter. Today's Q2 results prove we are moving in the right direction. I am very proud of the Sanofi teams around the world for their commitment to improving people's lives. That is what makes this possible and excites me for our future. Check out the video to learn more about our progress. ▶️ public_profile__posts 2,692 39 Comments Copy LinkedIn Facebook X Report this post Belén Garijo Belén Garijo 2mo Report this post Belén Garijo shared this I've come to believe innovation often starts with something simple: a human "why." That's the origin story of every breakthrough we make in service of human progress. Few stories illustrate this better than Santiago Ramón y Cajal. At a time when leading scientists believed the brain was a reticulum, an interconnected network, Cajal challenged the consensus. Working in near isolation, he discovered that the nervous system was composed of individual cells, or neurons. With no scientific consensus on his side, he followed the facts with curiosity, discipline, and courage. That was enough to earn him the Nobel Prize in Medicine, the first ever awarded to a Spanish scientist, and to lay the foundation for modern neuroscience. That very foundation still supports the treatments we work to develop today. This story is now a children's book I'm proud to support as part of the INDOMITABLE collection by #TWFoundation . It resonates well with our purpose at Sanofi to always chase the miracles of science, which starts with curiosity like Cajal's. If you know a young person with that spark, I encourage you to share this book with them. Investing in the next generation is the most important contribution any of us can make to the future of science. Spanish: https://lnkd.in/eqD_PmzT English: https://lnkd.in/e5ZF85b9 public_profile__posts 1,773 54 Comments Copy LinkedIn Facebook X Report this post Belén Garijo Belén Garijo 3mo Report this post Belén Garijo shared this Back from an energizing trip to China last week with Thomas Triomphe and Olivier Charmeil . After three days, here are my top takeaways. 🟣 China's innovation capacity is truly impressive and leveraging this local innovation will be one of the key pillars to Sanofi’s future success. Its vibrant ecosystem combines decision-making with speed and agility, pro-innovation policies, and exceptional talent. 🟣Our local teams drive our purpose forward. I connected with 3,000+ employees during our fireside chat and watched three groundbreaking demonstrations of our AI capabilities. Witnessing our four-decade journey in China come to life through the work of our people was the highlight of my trip. 🟣What's being built here today is a glimpse of what's possible for patients. As science and technology converge at a speed that completely reshapes how we innovate, it's a powerful reminder of why we do this work: for the patients around the world counting on us to move faster, think bolder, and deliver. Innovation is the most powerful expression of our commitment to them. A big thank you to Wayne Shi and the China team for a highly productive week! public_profile__posts 2,071 28 Comments Copy LinkedIn Facebook X Report this post Belén Garijo Belén Garijo 3mo Report this post Belén Garijo shared this Proud of Sanofi as the first pharma company to publicly report co-created patient metrics with 80+ patient organizations worldwide. I have always believed that trust is earned through actions. And in healthcare, trust is key, because the people we serve are counting on us at the most vulnerable moments of their lives. To every patient advocate, healthcare leader, and industry colleague: I invite you to explore what we've learned. Sanofi Sanofi 3mo Belén Garijo shared this Three years ago, we made a set of commitments to the patient community. Today, we're delivering. Our 2025 Patient Community Promise Report shows real progress: ✔️ 100% of our clinical studies informed directly by patients ✔️ Patient satisfaction in ease of working together jumped from 61% to 91% ✔️ Patient-relevant drug label strategy in 100% of Phase 3 programs We were the first pharma company to publicly report these metrics, co-created with 80+ patient organizations worldwide. And we are going beyond numbers: 🟣 20+ local impact highlights across 11+ disease areas 🟣 Fully digital and accessible experience 🟣 25+ performance metrics involving 8 core functions Working for patients was never enough. We work with them. And that changes everything. Read the 2025 Patient Community Promise Report: http://spkl.io/60447D5do #PatientCommunityPromise #IntegratedPatientEngagement public_profile__posts 998 13 Comments Copy LinkedIn Facebook X Report this post Belén Garijo Belén Garijo 4mo Report this post Belén Garijo shared this Last Saturday, we welcomed another medical doctor in the Garijo family. Congratulations, dear Miguel Megias Garijo , on your graduation as a medical doctor. I am proud that you carry forward our family's passion to serve patients. This generation of doctors will experience a new medical environment in which they will be challenged to go above and beyond. I am encouraged by their fresh vision and their passion to care for patients. That is exactly what medicine needs. Together with the resources and technology they have at hand, they will achieve great things. Witnessing this proud moment with Miguel and his class reminded me of my own graduation more than 30 years ago. It inspired me to renew my Hippocratic oath, because I feel that everything I once swore to uphold remains as relevant today as ever, in all that I do as a leader of a patient-centric pharma company like Sanofi . public_profile__posts 3,559 77 Comments Copy LinkedIn Facebook X Report this post Belén Garijo Belén Garijo 4mo Report this post Belén Garijo shared this Breakthroughs make headlines. But the truth is, that is a fraction of the whole picture. What we don't talk about enough are the systems behind the breakthroughs that determine whether our science becomes medicines and vaccines. Three weeks in at Sanofi , I've spent time up close with the engines (and the people behind those engines) that drive our innovation forward, from our historic R&D and Manufacturing site in Vitry-sur-Seine, France, to our state-of-the-art campus in Cambridge, Massachusetts. What I discovered is that innovation is our lifeblood – the connective tissue across thousands of decisions, pivots, and learnings that must align for a discovery to materialize. From early discovery and rigorous quality standards, to the manufacturing discipline and supply chain precision that turns a breakthrough into something we can deliver reliably, at scale, across the world. Our next chapter will not just be about what we discover and develop. It will be about building the capabilities and agility to bring new therapies to the patients urgently counting on us. That is the work ahead. public_profile__posts 2,490 59 Comments Copy LinkedIn Facebook X Report this post Belén Garijo Belén Garijo 4mo Report this post Belén Garijo shared this Thank you Aditi ! Energized and ready to mobilize the sanofi teams to make even a bigger impact to patients together Aditi Tuteja Aditi Tuteja 4mo Belén Garijo shared this Watching Belén Garijo step back into Sanofi , as our first female CEO, was simply momentous and carried a weight that went beyond ceremony. This is someone who knows this organization from inside, its legacy, its people, its potential and its responsibility to the patients. Her return feels like a homecoming with purpose. What made her opening remarks so powerful was their authenticity. Every word felt earned, rooted in real experience and genuine conviction. That rare combination of clarity, humility, and quiet authority reminded the room what makes her a force in biopharma. She spoke of where this organization can go not as a distant ambition, but already within reach if we move forward #together . That sense of collective ownership inspires greatly. The zoom reactions didn’t stop coming on this webcast ❤️👏🏻👍😄❤️👏🏻😄👍❤️👏🏻 Excited about what we build next with her. #sanofistories #leadership public_profile__posts 474 6 Comments Copy LinkedIn Facebook X Report this post Belén Garijo reacted on this Report this post Belén Garijo reacted on this Merck Group Merck Group 1w Belén Garijo reacted on this Khadija Ben Hammada , unsere Chief People Officer, ist für die Auszeichnung „CHRO of the Year 2026" nominiert und wir können sie dabei unterstützen! 🎉 Jedes Jahr kürt das Personalmagazin gemeinsam mit Marsh Top-Managerinnen und -Manager, die im Personalbereich die entscheidenden Zukunftsthemen setzen, die Diskussion in Wirtschaft und HR mitprägen, Leuchtturmprojekte umsetzen und als Persönlichkeit überzeugen. Für 2026 stehen sechs Namen auf der Liste, Khadija ist eine von ihnen. Wer den Titel erhält, entscheiden wir mit unserer Stimme. Jetzt abstimmen: vom 21. September bis 2. Oktober 2026 unter http://ms.spr.ly/6046agOLY Jede Stimme zählt! Verliehen wird die Auszeichnung am 10. November 2026 in München. public_profile__reactions 716 26 Comments Copy LinkedIn Facebook X Report this post Belén Garijo liked this Report this post Belén Garijo liked this Brendan O'Callaghan Brendan O'Callaghan 1w Belén Garijo liked this For more than 110 years, Sanofi has been advancing healthcare in Canada. Yesterday marked a new milestone in this proud heritage, as we inaugurated our new Charles Best vaccine manufacturing facility, reinforcing our long-term commitment to protecting public health in Canada and beyond. This state-of-the-art, advanced biomanufacturing facility builds on decades of expertise as the world's leading influenza vaccine producer and strengthens our ability to manufacture the highest-quality vaccines at scale, faster and more reliably, reinforcing supply resilience for Canadians and citizens in more than 50 countries around the world who will benefit from this investment and the work of our talented and committed teams. Indeed, more than a ribbon-cutting, today’s event is a proud moment for the dedicated women and men of Sanofi Toronto, whose hard work every day makes days like this possible: the scientists, engineers and plant operating teams. They are the makers, the ones who turn the miracles of science into the reality of vaccine doses to protect the health of citizens in Canada and around the world. As one of Sanofi’s five global R&D hubs, Canada plays an important role in our global network. We have invested more than $1.5B in R&D in Canada over the past decade, alongside continued investment in our world-class biomanufacturing capabilities. We’re grateful for the partnership with the Government of Canada, the Province of Ontario and the City of Toronto as we continue to advance solutions that make a difference for Canadians. Read more: https://lnkd.in/er3F7AVJ #WeNeverSettle #ManufacturingAndSupply Mélanie Joly Doug Ford Sylvia Jones Michael Kerzner DPM Victor Fedeli Pam S. Kate Winchester James Guy Thomas Triomphe Olivia Chow Marjorie Michel public_profile__reactions 440 4 Comments Copy LinkedIn Facebook X Report this post Brendan O'Callaghan Belén Garijo reacted on this Report this post Belén Garijo reacted on this Maria Cudeiro Torruella (BSc, MBA) Maria Cudeiro Torruella (BSc, MBA) 2w Belén Garijo reacted on this 𝗟𝗼𝘀 𝗱𝗼𝗺𝗶𝗻𝗴𝗼𝘀 𝗲𝘀𝗰𝗿𝗶𝗯𝗼. No siempre apetece. Llevo más de un año haciéndolo. Escribo #Bellezaconcabeza porque estoy harta de ver a mujeres decidir sobre su piel, su pelo y su cuerpo a base de ruido. Soy farmacéutica y dirijo un negocio de medicina estética: sé lo que dice la evidencia y sé lo que se vende. No siempre son lo mismo. Nada que importe a largo plazo se construye en un arranque de inspiración. Se construye los domingos. Capítulo a capítulo. Cuando nadie te ve y nadie te lo pide. 𝗘𝗹 𝗽𝗼𝘁𝗲𝗻𝗰𝗶𝗮𝗹 𝗻𝗼 𝘀𝗲 𝗱𝗲𝘀𝗯𝗹𝗼𝗾𝘂𝗲𝗮 𝘀𝗼𝗹𝗼. Se desbloquea eligiendo cada semana en qué gastas las horas que nadie te ha asignado. 📖 Sale este otoño con Alienta Editorial. GRUPO EDITORIAL PLANETA ✍️ Lista de espera: https://lnkd.in/enVncJ-n ¿Y tú, qué haces los domingos? #BellezaConCabeza #skincare #MedicinaEstética #Liderazgo public_profile__reactions 183 29 Comments Copy LinkedIn Facebook X Report this post Maria Cudeiro Torruella (BSc, MBA) Belén Garijo reacted on this Report this post Manuela Buxo Manuela Buxo 3w Belén Garijo reacted on this I'm truly honored to be part of the new Sanofi Executive Committee. I’m genuinely excited about what we can accomplish together as a team and with our people for patients over the next decade and beyond. Thank you Belén for your trust! Sanofi Sanofi 4w Belén Garijo reacted on this Today, we’re proud to welcome Sanofi’s new Executive Committee, led by Belén Garijo . A team bringing together diverse expertise and experiences, united by a shared vision for what comes next. 🟣 Manuela Buxo , EVP, Head of Specialty Care 🟣 Paulo Fontoura , EVP, Head of Research and Development 🟣 Thomas Grenier , EVP, General Medicines 🟣 Jamie Haney , EVP, General Counsel 🟣 Veronique JAILLET, Interim Chief People Officer 🟣 Brendan O'Callaghan , EVP, Manufacturing and Supply 🟣 François-Xavier Roger , EVP, Chief Financial Officer 🟣 Thomas Triomphe , EVP, Vaccines This marks the beginning of a new chapter. And there’s plenty more to discover along the way. Welcome to our new Executive Committee! Learn more about the team: http://spkl.io/60477uHuU public_profile__reactions 422 56 Comments Copy LinkedIn Facebook X Report this post Belén Garijo reacted on this Report this post Belén Garijo reacted on this Jean-Charles Wirth Jean-Charles Wirth 4w Belén Garijo reacted on this Proud to share that I've joined American Cancer Society 's CEOs Against Cancer - New England Chapter . Cancer doesn't pick industries or borders. It touches all of us – colleagues, friends, family. That's exactly why initiatives like this matter: bringing together leaders who are committed to turning that shared urgency into action, helping our employees, customers, and communities stay healthy. At Merck Life Science , impacting life and health with science is what we do. This is a natural extension of that commitment, and a responsibility I take seriously. More to come. Grateful to be part of this community! public_profile__reactions 677 14 Comments Copy LinkedIn Facebook X Report this post Jean-Charles Wirth Chief Executive Officer Sanofi May 2026 - Present 5 months Chief Executive Officer May 2026 - Present 5 months Board Member European Innovation Council Jan 2026 - Present 9 months The EIC is Europe’s flagship innovation program to identify, develop and scale up breakthrough technologies and game changing innovations. As a Board member, I advise the Commission on how to boost European sovereignty by funding startups and collaborations across critical growth industries. European Innovation Council Jan 2026 - Present 9 months The EIC is Europe’s flagship innovation program to identify, develop and scale up breakthrough technologies and game changing innovations. As a Board member, I advise the Commission on how to boost European sovereignty by funding startups and collaborations across critical growth industries. Merck Group 15 years 4 months Chair of the Executive Board and CEO of Merck Merck Group May 2021 - Apr 2026 5 years Vice Chairman of the Executive Board | Deputy CEO Merck Group Jan 2021 - May 2021 5 months Vice Chairman of the Executive Board | Deputy CEO | Healthcare CEO Merck Group Jul 2020 - Jan 2021 7 months Darmstadt, Hesse, Germany CEO Healthcare, Member of the Executive Board Merck Group Jan 2015 - Jul 2020 5 years 7 months Darmstadt, Germany Responsible for the Healthcare business at Merck President & CEO of Biopharma (formerly Merck Serono) Merck Group Oct 2013 - Dec 2014 1 year 3 months Darmstadt, Germany Chief Operating Officer of Biopharma (formerly Merck Serono) Merck Group Jan 2011 - Sep 2013 2 years 9 months Darmstadt, Germany 15 years 4 months Chair of the Executive Board and CEO of Merck Merck Group May 2021 - Apr 2026 5 years Chair of the Executive Board and CEO of Merck May 2021 - Apr 2026 5 years Vice Chairman of the Executive Board | Deputy CEO Merck Group Jan 2021 - May 2021 5 months Vice Chairman of the Executive Board | Deputy CEO Jan 2021 - May 2021 5 months Vice Chairman of the Executive Board | Deputy CEO | Healthcare CEO Merck Group Jul 2020 - Jan 2021 7 months Darmstadt, Hesse, Germany Vice Chairman of the Executive Board | Deputy CEO | Healthcare CEO Jul 2020 - Jan 2021 7 months Darmstadt, Hesse, Germany CEO Healthcare, Member of the Executive Board Merck Group Jan 2015 - Jul 2020 5 years 7 months Darmstadt, Germany Responsible for the Healthcare business at Merck CEO Healthcare, Member of the Executive Board Jan 2015 - Jul 2020 5 years 7 months Darmstadt, Germany Responsible for the Healthcare business at Merck President & CEO of Biopharma (formerly Merck Serono) Merck Group Oct 2013 - Dec 2014 1 year 3 months Darmstadt, Germany President & CEO of Biopharma (formerly Merck Serono)

Oct 2013 - Dec 2014 1 year 3 months Darmstadt, Germany Chief Operating Officer of Biopharma (formerly Merck Serono) Merck Group Jan 2011 - Sep 2013 2 years 9 months Darmstadt, Germany Chief Operating Officer of Biopharma (formerly Merck Serono) Jan 2011 - Sep 2013 2 years 9 months Darmstadt, Germany Sanofi 8 years Senior Vice President, Global Operations Region Europe Sanofi Jan 2006 - Dec 2010 5 years Greater Paris Metropolitan Region General Manager, Spain Sanofi Jan 2003 - Dec 2005 3 years Senior Vice President, Global Operations Region Europe Sanofi Jan 2006 - Dec 2010 5 years Greater Paris Metropolitan Region Senior Vice President, Global Operations Region Europe Jan 2006 - Dec 2010 5 years Greater Paris Metropolitan Region General Manager, Spain Sanofi Jan 2003 - Dec 2005 3 years General Manager, Spain Jan 2003 - Dec 2005 3 years Global Vice President Oncology Aventis Jan 2000 - Dec 2002 3 years New Jersey Global Vice President Oncology Jan 2000 - Dec 2002 3 years Business Unit Director of Oncology Rhone-Poulenc Rorer Jan 1996 - Dec 1999 4 years Spain Business Unit Director of Oncology Rhone-Poulenc Rorer Jan 1996 - Dec 1999 4 years University of Alcala de Henares MD, PhD medical doctor in clinical pharmacology 1984 - 1989 University of Alcala de Henares MD, PhD medical doctor in clinical pharmacology Honors & Awards Recipient of Honorary Award at German Diversity Awards BeyondGenderAgenda Oct 2022 Recipient of Honorary Award at German Diversity Awards BeyondGenderAgenda Top 30 in Fortune Power Women List and Fortune Most Powerful Women Fortune Oct 2022 Top 30 in Fortune Power Women List and Fortune Most Powerful Women View Belén’s full profile See who you know in common Contact Belén directly Other similar profiles Stefan Oschmann Stefan Oschmann Qanatpharma 56K followers Germany View Profile Stefan Oschmann Franca Lena Maischein Franca Lena Maischein Merck Group 4K followers Frankfurt Rhine-Main Metropolitan Area View Profile Franca Lena Maischein Gernot W. Gernot W. RECIPE Chemicals + Instruments GmbH 1K followers Bavaria, Germany View Profile RECIPE Chemicals + Instruments GmbH Boris A. Hesser PhD Boris A. Hesser PhD Healthcare Business of Merck 2K followers Frankfurt Rhine-Main Metropolitan Area View Profile Boris A. Hesser PhD Healthcare Business of Merck Peter Guenter Peter Guenter Vicore Pharma AB 13K followers Switzerland View Profile Vicore Pharma AB Dietmar Gross Dietmar Gross www.clinpharmore.com 917 followers Berlin Metropolitan Area View Profile www.clinpharmore.com Frank Wallner Frank Wallner Dept of Otolaryngology 78 followers Frankfurt Rhine-Main Metropolitan Area View Profile Dept of Otolaryngology Gabriel Baertschi Gabriel Baertschi Idorsia Pharmaceuticals Ltd 9K followers Düsseldorf View Profile Gabriel Baertschi Idorsia Pharmaceuticals Ltd Ralf Wulkow Ralf Wulkow Freelance 1K followers Riedstadt View Profile Bernhard Ehmer Bernhard Ehmer Biotest AG 518 followers Dreieich View Profile Jit Saini Jit Saini GE HealthCare 4K followers United Kingdom View Profile Jakob Hoppe Jakob Hoppe Merck Healthcare 4K followers Frankfurt View Profile Merck Healthcare Michael Mehler Michael Mehler CM & A Pharma GmbH 896 followers Greater Munich Metropolitan Area View Profile CM & A Pharma GmbH Jürgen Ebert Jürgen Ebert JEmedis 3K followers Berlin View Profile Karl- Heinz Konz Karl- Heinz Konz Medconsult 48 followers Cologne Bonn Region View Profile Karl- Heinz Konz Marcos Beyeler Marcos Beyeler Merck Group 2K followers Kelkheim View Profile Johannes Kremer Johannes Kremer DiaMed Beratungsgesellschaft für pharmazeutische Unternehmen mbH 292 followers Münster View Profile Johannes Kremer DiaMed Beratungsgesellschaft für pharmazeutische Unternehmen mbH Margit Gieseler Margit Gieseler FREEZE-DRYING OF PHARMACEUTICALS AND BIOLOGICALS; FOOD<br><br>Consulting <br><br>Project Management<br><br>Freeze-Drying Process Design and Optimization:<br>- MTM and SMART Freeze Dryer Technology<br>- TEMPRIS wireless temperature sensors<br>- Controlled nucleation<br><br>Physicochemical Characterization of Materials<br>- Freeze Dry Microscopy<br>- Karl Fischer Residual Moisture Analysis<br>- Specific Surface Area<br>- Mercury Intrusion Porosimetry <br>- Scanning Electron Microscopy<br><br>Scale-Up of Freeze-Drying Cycles & Technical Transfer 221 followers Greater Wurzburg Area View Profile Margit Gieseler FREEZE-DRYING OF PHARMACEUTICALS AND BIOLOGICALS; FOOD<br><br>Consulting <br><br>Project Management<br><br>Freeze-Drying Process Design and Optimization:<br>- MTM and SMART Freeze Dryer Technology<br>- TEMPRIS wireless temperature sensors<br>- Controlled nucleation<br><br>Physicochemical Characterization of Materials<br>- Freeze Dry Microscopy<br>- Karl Fischer Residual Moisture Analysis<br>- Specific Surface Area<br>- Mercury Intrusion Porosimetry <br>- Scanning Electron Microscopy<br><br>Scale-Up of Freeze-Drying Cycles & Technical Transfer Prof. Helga Rübsamen-Schaeff Prof. Helga Rübsamen-Schaeff acatech – Deutsche Akademie der Technikwissenschaften 1K followers Greater Dusseldorf Area View Profile Prof. Helga Rübsamen-Schaeff acatech – Deutsche Akademie der Technikwissenschaften Urmi Prasad Richardson Urmi Prasad Richardson Global executive with 25+ years of experience in conception to realisation of business plans and commercial operations, in the areas of biotechnology and healthcare. Leadership experience in strategic planning, business development, product commercialization and new market expansion (EMEA, APAC, North & South Americas). Accomplished programme manager with demonstrated ability to lead global and cross-functional project teams. Deep understanding of Healthcare markets and driving sustainable growth in emerging markets, including change through policy and public affairs. Proven track record in translating innovation into business results. Reliable and visible leadership in transformational times, being a change catalyst as well as an empowering coach for delivering high performance coupled with collaborative behaviours. Embracing cultural evolution to build alliances and mobilize partners for success. <br><br>Portfolio and technical experience in molecular diagnostics, infectious diseases, immunohematology, medtech, point-of-care, cancer genomics, respiratory disease. <br><br>Fluent in English, French, Hindi. Conversational in German, Spanish, Bengali. <br><br>Skills and Expertise:<br>- Global Strategy and P&L <br>- Global Markets & Business Development <br>- Global Business Partner Management<br>- M&A for technology platforms<br>- Transformational Leadership<br>- Operational Model Optimization 4K followers Greater Munich Metropolitan Area View Profile Urmi Prasad Richardson Global executive with 25+ years of experience in conception to realisation of business plans and commercial operations, in the areas of biotechnology and healthcare. Leadership experience in strategic planning, business development, product commercialization and new market expansion (EMEA, APAC, North & South Americas). Accomplished programme manager with demonstrated ability to lead global and cross-functional project teams. Deep understanding of Healthcare markets and driving sustainable growth in emerging markets, including change through policy and public affairs. Proven track record in translating innovation into business results. Reliable and visible leadership in transformational times, being a change catalyst as well as an empowering coach for delivering high performance coupled with collaborative behaviours. Embracing cultural evolution to build alliances and mobilize partners for success. <br><br>Portfolio and technical experience in molecular diagnostics, infectious diseases, immunohematology, medtech, point-of-care, cancer genomics, respiratory disease. <br><br>Fluent in English, French, Hindi. Conversational in German, Spanish, Bengali. <br><br>Skills and Expertise:<br>- Global Strategy and P&L <br>- Global Markets & Business Development <br>- Global Business Partner Management<br>- M&A for technology platforms<br>- Transformational Leadership<br>- Operational Model Optimization Explore more posts Joachim Eeckhout Knowbio GmbH • 14K followers Are French biotechs coordinating their announcements on purpose? Here’s what our homepage looks like today: 1. MaaT Pharma has received a “negative trend” opinion in response to its request for EMA to re-examine its opposition to approving a microbiome therapy. 2. Axoltis Pharma’s NX210c missed the primary endpoint of a Phase 2 trial in amyotrophic lateral sclerosis (ALS), but post-hoc analyses showing slower functional decline are giving the company enough encouragement to plan further development. 3. Cellectis is abandoning development of its two internal allogeneic CAR-T programs and repositioning itself as an in vivo gene editing company focused initially on cardiovascular disease. 4. GENFIT acquired nangibotide from Inotrem in the summer and plans to start a Phase 2a trial in acute-on-chronic liver failure (ACLF) in the fourth quarter. ✅ Don’t miss the next biotech story from European (French?) Biotechnology Magazine Subscribe here: https://lnkd.in/e5KjDRmt 22 1 Comment Joachim Eeckhout Knowbio GmbH • 14K followers Are French biotechs coordinating their announcements on purpose? Here’s what our homepage looks like today: 1. MaaT Pharma has received a “negative trend” opinion in response to its request for EMA to re-examine its opposition to approving a microbiome therapy. 2. Axoltis Pharma’s NX210c missed the primary endpoint of a Phase 2 trial in amyotrophic lateral sclerosis (ALS), but post-hoc analyses showing slower functional decline are giving the company enough encouragement to plan further development. 3. Cellectis is abandoning development of its two internal allogeneic CAR-T programs and repositioning itself as an in vivo gene editing company focused initially on cardiovascular disease. 4. GENFIT acquired nangibotide from Inotrem in the summer and plans to start a Phase 2a trial in acute-on-chronic liver failure (ACLF) in the fourth quarter. ✅ Don’t miss the next biotech story from European (French?) Biotechnology Magazine Subscribe here: https://lnkd.in/e5KjDRmt Bpifrance Large Venture 9K followers We’re proud to announce the acquisition of our portfolio company ImCheck Therapeutics by Ipsen for a total potential consideration up to €1B. This acquisition follows robust clinical results in the treatment of acute myeloid leukemia (AML), validating the potential of ICT01 — ImCheck’s first-in-class monoclonal antibody targeting BTN3A, a key immune checkpoint molecule broadly expressed across cancers. 🔗 https://lnkd.in/d6ncQ9TY Nicolas Dufourcq, Paul-François Fournier, Maïlys Ferrere, Laurent Arthaud, Laurent Higueret, Thibaut Roulon #Biotech #Innovation #Exit 125 Bpifrance Large Venture We’re proud to announce the acquisition of our portfolio company ImCheck Therapeutics by Ipsen for a total potential consideration up to €1B. This acquisition follows robust clinical results in the treatment of acute myeloid leukemia (AML), validating the potential of ICT01 — ImCheck’s first-in-class monoclonal antibody targeting BTN3A, a key immune checkpoint molecule broadly expressed across cancers. 🔗 https://lnkd.in/d6ncQ9TY Nicolas Dufourcq, Paul-François Fournier, Maïlys Ferrere, Laurent Arthaud, Laurent Higueret, Thibaut Roulon #Biotech #Innovation #Exit CellProthera SAS 5K followers 🔎 What Does 2026 Hold For Biopharma? That's the question Scrip asked various experts, including our CEO, Matthieu de Kalbermatten. In this article, enthusiastic predictions from industry leaders for ongoing progress in obesity, oncology, immunology, neuroscience and more were supported by optimism for the potential of AI and other technological advances to enable breakthroughs in processes as well as pipelines. In the part focused on R&D and Innovation, Matthieu de Kalbermatten shared his opinion: "The year 2026 should see renewed interest in regenerative medicine…" To read the full article, click here 👉 https://lnkd.in/eFg9pNAD #CellTherapy #RegenerativeMedicine #StemCells 15 1 Comment CellProthera SAS 🔎 What Does 2026 Hold For Biopharma? That's the question Scrip asked various experts, including our CEO, Matthieu de Kalbermatten. In this article, enthusiastic predictions from industry leaders for ongoing progress in obesity, oncology, immunology, neuroscience and more were supported by optimism for the potential of AI and other technological advances to enable breakthroughs in processes as well as pipelines. In the part focused on R&D and Innovation, Matthieu de Kalbermatten shared his opinion: "The year 2026 should see renewed interest in regenerative medicine…" To read the full article, click here 👉 https://lnkd.in/eFg9pNAD #CellTherapy #RegenerativeMedicine #StemCells GoGetLicense 196 followers DEAL SPOTLIGHT: Pfizer & Medicus Pharma — Exclusive Global Co-Development & License for CD228V Oncology ADC On paper, it looks like a standard licensing agreement. But behind the announcement, the commercial logic reveals a lot about how big pharma is prioritizing pipeline assets following massive M&A deals. Pfizer originally acquired CD228V through its $43B Seagen buyout, advancing it into Phase 1 before strategic portfolio pruning paused the program. Medicus Pharma stepped in to take over global development, manufacturing, and commercialization rights across all human disease indications, giving the asset a dedicated operational home. The Structure & Financial Terms: - Financials: Medicus provides $27M in near-term payments ($12M upfront at signing plus an additional $15M on the first anniversary in September 2027). Pfizer is contributing $2M in non-refundable development funding to kickstart operations. Total milestone payments can exceed $1B based on clinical, regulatory, and commercial targets, backed by tiered low double-digit net sales royalties. - Territory & Rights: Worldwide, exclusive, sublicensable license covering all human disease indications. Medicus shoulders full responsibility for clinical advancement and regulatory filings. - Asset & Stage: CD228V (PF-08046031), an antibody-drug conjugate targeting melanotransferrin (CD228/MFI2) conjugated to an MMAE payload via a protease-cleavable linker. Currently at Phase 1 stage for advanced melanoma and solid tumors. Why This Matters for BD Teams: When large pharma consolidates, high-potential programs often get sidelined simply because internal development bandwidth gets redirected. Structuring a staggered upfront ($12M now, $15M in year two) gives a specialized biotech immediate runway without triggering immediate balance sheet shocks. Pfizer retains the core patent estate and keeps an option to co-fund pivotal trials, preserving massive upside if Medicus successfully validates the mechanism. 🚀 Have technology, research, or IP ready for licensing? Showcase it and connect with potential partners on GoGetLicense. 🌐 https://gogetlicense.com #Licensing #BusinessDevelopment #TechTransfer #IPStrategy #IntellectualProperty 2 DEAL SPOTLIGHT: Pfizer & Medicus Pharma — Exclusive Global Co-Development & License for CD228V Oncology ADC On paper, it looks like a standard licensing agreement. But behind the announcement, the commercial logic reveals a lot about how big pharma is prioritizing pipeline assets following massive M&A deals. Pfizer originally acquired CD228V through its $43B Seagen buyout, advancing it into Phase 1 before strategic portfolio pruning paused the program. Medicus Pharma stepped in to take over global development, manufacturing, and commercialization rights across all human disease indications, giving the asset a dedicated operational home. The Structure & Financial Terms: - Financials: Medicus provides $27M in near-term payments ($12M upfront at signing plus an additional $15M on the first anniversary in September 2027). Pfizer is contributing $2M in non-refundable development funding to kickstart operations. Total milestone payments can exceed $1B based on clinical, regulatory, and commercial targets, backed by tiered low double-digit net sales royalties. - Territory & Rights: Worldwide, exclusive, sublicensable license covering all human disease indications. Medicus shoulders full responsibility for clinical advancement and regulatory filings. - Asset & Stage: CD228V (PF-08046031), an antibody-drug conjugate targeting melanotransferrin (CD228/MFI2) conjugated to an MMAE payload via a protease-cleavable linker. Currently at Phase 1 stage for advanced melanoma and solid tumors. Why This Matters for BD Teams: When large pharma consolidates, high-potential programs often get sidelined simply because internal development bandwidth gets redirected. Structuring a staggered upfront ($12M now, $15M in year two) gives a specialized biotech immediate runway without triggering immediate balance sheet shocks. Pfizer retains the core patent estate and keeps an option to co-fund pivotal trials, preserving massive upside if Medicus successfully validates the mechanism. 🚀 Have technology, research, or IP ready for licensing? Showcase it and connect with potential partners on GoGetLicense. 🌐 https://gogetlicense.com #Licensing #BusinessDevelopment #TechTransfer #IPStrategy #IntellectualProperty Sachs Associates 5K followers BIOMUNEX Pharmaceuticals is a clinical-stage biopharmaceutical company based in Paris, led by an international team, focused on the discovery and development of disruptive immuno-therapeutics in oncology, thanks to its proprietary next-generation bi- and multi-specific antibody, the BiXAb® platform. Biomunex is developing a disruptive biological approach, the MAIT-engagers, that redirect MAIT cells to kill cancer cells, which may become a true game changer in the field of cancer immunotherapy. Meet BIOMUNEX PHARMACEUTICALS @ #Sachs_OIF More info @ https://lnkd.in/dT4gH2mX #OncologyInnovation #BioPharma #CancerTherapeutics #ImmunoOncology #BiotechInvestment #LifeSciences #PrecisionMedicine #OncologyDeals #BioPharmaIndustry #BiotechConference #CancerResearch #TargetedTherapies #TherapeuticInnovation #HealthcareInvestment #InvestmentOpportunity #SachsForum #JPMWeek #OncologyConference 3 Sachs Associates BIOMUNEX Pharmaceuticals is a clinical-stage biopharmaceutical company based in Paris, led by an international team, focused on the discovery and development of disruptive immuno-therapeutics in oncology, thanks to its proprietary next-generation bi- and multi-specific antibody, the BiXAb® platform. Biomunex is developing a disruptive biological approach, the MAIT-engagers, that redirect MAIT cells to kill cancer cells, which may become a true game changer in the field of cancer immunotherapy. Meet BIOMUNEX PHARMACEUTICALS @ #Sachs_OIF More info @ https://lnkd.in/dT4gH2mX #OncologyInnovation #BioPharma #CancerTherapeutics #ImmunoOncology #BiotechInvestment #LifeSciences #PrecisionMedicine #OncologyDeals #BioPharmaIndustry #BiotechConference #CancerResearch #TargetedTherapies #TherapeuticInnovation #HealthcareInvestment #InvestmentOpportunity #SachsForum #JPMWeek #OncologyConference Biomapas 46K followers Where should small biotechs begin when planning an early‑phase oncology trial? 📚 In this short video from our latest Biomapas Insights episode, Jean-Luc Béjot – an independent consultant with 35+ years of experience in clinical development and operations – joins Arturas Pazera, Senior Clinical Project Manager at Biomapas to share the foundational principles every sponsor should consider before designing their first‑in‑human oncology study: ✅ What sponsors should define before drafting their protocol. ✅ How product type influences early‑phase trial design. ✅ Why indication selection matters early on. Watch the full conversation to learn more 👉 https://lnkd.in/ezVNkVrw #clinicalresearch #earlyphase #oncology 27 Where should small biotechs begin when planning an early‑phase oncology trial? 📚 In this short video from our latest Biomapas Insights episode, Jean-Luc Béjot – an independent consultant with 35+ years of experience in clinical development and operations – joins Arturas Pazera, Senior Clinical Project Manager at Biomapas to share the foundational principles every sponsor should consider before designing their first‑in‑human oncology study: ✅ What sponsors should define before drafting their protocol. ✅ How product type influences early‑phase trial design. ✅ Why indication selection matters early on. Watch the full conversation to learn more 👉 https://lnkd.in/ezVNkVrw #clinicalresearch #earlyphase #oncology Biofocus Talent 342 followers Sanofi, Servier, Pierre Fabre, Ipsen, LFB, and Théa are leaving France's main industry association (Leem) to form their own syndicate. Their focus: faster decision-making, innovation advocacy, and addressing France's competitiveness gap. The stat that stands out: 40% of drugs approved in Europe aren't available in France. For those of us in life sciences recruitment, this signals shifting priorities in how French pharma wants to position itself globally If this move ultimately improves patient access to innovative treatments, then it's a step in the right direction ! #LifeSciences #BioFocusTalent #IndustryNews 2 Biofocus Talent Sanofi, Servier, Pierre Fabre, Ipsen, LFB, and Théa are leaving France's main industry association (Leem) to form their own syndicate. Their focus: faster decision-making, innovation advocacy, and addressing France's competitiveness gap. The stat that stands out: 40% of drugs approved in Europe aren't available in France. For those of us in life sciences recruitment, this signals shifting priorities in how French pharma wants to position itself globally If this move ultimately improves patient access to innovative treatments, then it's a step in the right direction ! #LifeSciences #BioFocusTalent #IndustryNews Explore collaborative articles We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI. Others named Belén Garijo Belen G. Germany belen garijo megias Greater Murcia Metropolitan Area belen garijo megias Belén Garijo Taillefer Greater Málaga Metropolitan Area Belén Garijo Taillefer Ana Belén Garijo Valencia Ana Belén Garijo 6 others named Belén Garijo are on LinkedIn View Belén’s full profile Belén can introduce you to 10+ people at Sanofi New to LinkedIn? Join now By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . LinkedIn is better on the app Don’t have the app? Get it in the Microsoft Store.